| Current Price | $43.79 | Mkt Cap | $571.6M |
|---|---|---|---|
| Open | $43.60 | P/E Ratio | 49.24 |
| Prev. Close | $43.79 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $42.98 - $44.36 | Volume | 159,929 |
| 52-Wk Range | $33.80 - $56.16 | Avg. Daily Vol. | 123,465 |
| Current Price | $43.79 | Mkt Cap | $571.6M |
|---|---|---|---|
| Open | $43.60 | P/E Ratio | 49.24 |
| Prev. Close | $43.79 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $42.98 - $44.36 | Volume | 159,929 |
| 52-Wk Range | $33.80 - $56.16 | Avg. Daily Vol. | 123,465 |
The best Bull and Bear pitches based on recency and number of recommendations.
The next JAZZ in the making.
There are no pitches that meet the Top Bear criteria. Explain
If this upsets you, start recommending pitches below!
Read the most recent pitches from players about EGRX.
Recs
healthcarevalue
(68.41)
Submitted: 8/22/2017 11:47:27 PM :
Start Price:
$53.90
NASDAQ:EGRX Score:
-75.58
EGRX, Eagle Pharmaceuticals, is an attractive healthcare sector stock that is undervalued at this point in time with a price earnings ratio of about nine for the last twelve trailing months, a debt/equity ratio of negligible to nothing to speak of, and a return on invested capital of over seventy for the last twelve trailing months. The stock is currently towards the lower end of its 52 week range. The company's medical products related to both oncology and critical care are high need areas for its particular set of drugs. The company's specialty pharamceutical niche sets it apart as a differentiated area for potential growth and or an attractive candidate for potential acquisition by other pharmaceutical companies wishing to expand their research and development portfolios. Its market cap of under one billion, combined with its low debt and low price/earnings ratio, make it a potentially attractive acquisition candidate.
Recs
cibient
(20.62)
Submitted: 4/27/2016 3:31:57 PM :
Start Price:
$40.16
NASDAQ:EGRX Score:
-73.79
Bret Jensen - seekingalpha high conviction article on 4/22/16.
Recs
km00nster
(49.82)
Submitted: 4/10/2015 10:41:33 PM :
Start Price:
$48.89
NASDAQ:EGRX Score:
-92.97
One of the fastest growing biotech stocks out there. Expecting it to outperform for the next 5-10 years.
Find the members with the highest scoring picks in EGRX.
karakartal (< 20) Score: +346.60
The Score Leader is the player with the highest score across all their picks in EGRX.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| zackstracker1 | 28.88 | 2/29/2016 |
|
NS | $68.08 | -36.15% | +95.64% | +131.79 | 0 Comment | |
| jmdor2222 | 79.71 | 11/2/2016 |
|
5Y | $69.64 | -37.57% | +81.54% | +119.12 | 0 Comment | |
| germanjuggler | 70.59 | 6/10/2016 |
|
5Y | $52.81 | -17.68% | +81.73% | +99.41 | 0 Comment | |
| Turdtwistr | 52.94 | 2/5/2015 |
|
5Y | $19.01 | +128.67% | +86.33% | +42.34 | 0 Comment | |
| johnjm90 | < 20 | 12/17/2019 |
|
5Y | $60.61 | -28.28% | +19.32% | -47.60 | 0 Comment | |
| Bearbob63 | 29.33 | 2/19/2015 |
|
5Y | $34.67 | +25.38% | +82.28% | -56.90 | 0 Comment | |
| NoDoughBro | 71.80 | 3/3/2015 |
|
5Y | $37.76 | +15.12% | +80.51% | -65.39 | 0 Comment | |
| Ander89 | 88.28 | 3/3/2015 |
|
5Y | $37.76 | +15.12% | +80.51% | -65.39 | 0 Comment | |
| investat | 62.37 | 10/30/2017 |
|
1Y | $55.74 | -22.01% | +48.49% | -70.50 | 0 Comment | |
| GreenAB | 28.66 | 3/5/2015 |
|
NS | $39.40 | +10.33% | +81.19% | -70.86 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
